A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.

A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.